NCT04627948Completed
STHLM3 AS NorDCaP - a Followup Study of Men on Active Surveillance of Prostate Cancer
Source: ClinicalTrials.gov · Last updated 21 Jan 2025
Brief summary (registry, in English)
The aim of the STHLM3 AS NorDCaP study is to evaluate the Stockholm3 test in an active surveillance cohort to predict upgrading on rebiopsy. The study follows a paired design, evaluating our proposed protocol for follow up men on active surveillance with Stockholm3 versus the standard protocol according to national guidelines with PSA.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 199 (actual)
- First submitted
- 5 Nov 2020
- Start date
- 1 Jul 2019
- Primary completion date
- 1 Jul 2024
- Lead sponsor
- Karolinska Institutet
- Diseases
- Prostate cancer
- NCT number
- NCT04627948
What you commit to
- Study type: Observational
- Participants enrolled: 199
- From 1 Jul 2019 to the primary completion date, 1 Jul 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of treatment for prostate cancer; surgery, radiation, chemotherapy or hormonal treatment.
- Severe illnesses such as metastatic cancers, severe cardio-vascular disease or dementia
Who the study is looking for
- Men diagnosed with low-risk PC and currently on AS and planned for follow-up with systematic and/or fusion biopsies as following standard of care.
Age in the registry: 40 years to 75 years · Sex: Male · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska Institutet Coordinator of this site? Confirm its status | Stockholm | Sweden | Unknown status |
Related publications
- STHLM3 NorDCaP: prospective multicentre trial of Stockholm3 for active surveillance biopsy guidance.BJU Int · 2026 · PMID 42383465
This page is information, not medical advice. Discuss any trial with your doctor.